Colorectal NeoplasmsDeeP-CNCT01397747
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
An observational study of Colorectal Neoplasms and Digestive System Diseases, run by Exact Sciences Corporation at 184 sites in 2 countries.
Trial summary
The primary objective is to determine the sensitivity and specificity of the Exact Colorectal Cancer (CRC) screening test for colorectal cancer, using colonoscopy as the reference method. Lesions will be confirmed as malignant by histopathologic examination. Read more about this study
- Who is it for?
- Ages 50 to 84 yearsHealthy volunteers can take part
- Conditions the study is for
- Colorectal Neoplasms, Digestive System Diseases, Colonic Diseases
- How many people
- 12,776 participants
- Where
- 184 sitesin 2 countries
- Study dates
- Jun 2011to May 2013
- Phase
- Observational
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 84 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Patients at average risk of developing colorectal cancer.
Who may be able to join
- Subject is average risk for development of colorectal cancer (as defined by the inclusion and exclusion criteria below).
- Subject is able and willing to undergo a screening colonoscopy within 90 days of enrollment.
- Subject is 50 to 84 years of age inclusive.
- Subject is able to comprehend, sign, and date the written informed consent document to participate in the study.
- Subject is able and willing to provide stool samples according to written instructions provided to them.
Who cannot join
- Subject has any condition which, in the opinion of the investigator should preclude participation in the study.
- Subject has undergone colonoscopy within the previous nine (9) years.
- Subject has undergone any double-contrast barium enema, virtual (CT-based) colonoscopy, or flexible sigmoidoscopy within the previous five (5) years.
- Subject has a history of colorectal cancer or adenoma.
- Subject has a history of aerodigestive tract cancer.
- Subject has had a positive fecal occult blood test or FIT within the previous six (6) months.
Show all 19Show fewer
- Subject has had a prior colorectal resection for any reason other than sigmoid diverticular disease.
- Subject has had overt rectal bleeding, e.g., hematochezia or melena, within the previous 30 days. (Blood on toilet paper, after wiping, does not constitute rectal bleeding).
- Subject has a diagnosis or personal history of any of the following high-risk conditions for colorectal cancer:
- Inflammatory bowel disease (IBD) including chronic ulcerative colitis (CUC) and Crohn's disease.
- >= 2 first-degree relatives who have been diagnosed with colon cancer. (Note: first-degree relatives include parents, siblings and offspring).
- One first-degree relative with CRC diagnosed before the age of 60.
- Familial adenomatous polyposis (also referred to as "FAP", including attenuated FAP).
- Hereditary non-polyposis colorectal cancer syndrome (also referred to as "HNPCC" of "Lynch Syndrome").
- Other hereditary cancer syndromes including but are not limited to Peutz-Jeghers Syndrome, MYH-Associated Polyposis (MAP), Gardner's Syndrome, Turcot's (or Crail's) Syndrome, Cowden's Syndrome, Juvenile Polyposis, Cronkhite-Canada Syndrome, Neurofibromatosis and Familial Hyperplastic Polyposis.
- Subject has a family history of:
- Familial adenomatous polyposis (also referred to as "FAP").
- Hereditary non-polyposis colorectal cancer syndrome (also referred to as "HNPCC" or "Lynch Syndrome").
- Participation in any "interventional" clinical study within the previous 30 days in which an experimental treatment is administered or might be administered through a randomized assignment of the subject to one or more study groups.
Trial locations and contacts
184 sites in 2 countries.
184 sites in 2 countries
United States182 sites
Digestive Health Specialists, PA
Advance, North Carolina, 27006
Cancer Coalition of South Georgia
Albany, Georgia, 31707
Phoebe Digestive Health Center
Albany, Georgia, 31707
HealthCare Partners
Alhambra, California, 91801
HealthCare Partners
Arcadia, California, 91006
Valley Gastro Consultants
Arcadia, California, 91006
NCH Medical Group
Arlington Heights, Illinois, 60004
Northwest Community Hospital
Arlington Heights, Illinois, 60005
Asheville Gastroenterology Associates
Asheville, North Carolina, 28801
Atlanta Gastroenterology Associates
Atlanta, Georgia, 30308
Atlanta Gastroenterology Associates
Atlanta, Georgia, 30318
Professional Quality Research, Inc.
Austin, Texas, 78705
Professional Quality Research, Inc.
Austin, Texas, 78745
Professional Quality Research, Inc.
Austin, Texas, 78757
Main Line Gastroenterology
Bala-Cynwyd, Pennsylvania, 19004
Digestive Disease Associates, PA
Baltimore, Maryland, 21229
Gastrointestinal Diagnostic Center
Baltimore, Maryland, 21229
Gastroenterology & Nutritional Medical Services
Bastrop, Louisiana, 71220
Gastroenterology Associates
Baton Rouge, Louisiana, 70809
Northwest Gastroenterology Associates
Bellevue, Washington, 98004
Summit Medical Group
Berkeley Heights, New Jersey, 07922
Desert Oasis Healthcare
Bermuda Dunes, California, 92203
Binghamton Gastroenterology
Binghamton, New York, 13903
Achieve Clinical Research
Birmingham, Alabama, 35216
MediSpect
Boone, North Carolina, 28607
Boston Medical Center: Center for Digestive Disorders
Boston, Massachusetts, 02118
Boston Medical Center: Family Medicine
Boston, Massachusetts, 02118
Boston Medical Center
Boston, Massachusetts, 02118
Shapiro Ambulatory Care Center: Adult Primary Care
Boston, Massachusetts, 02118
Shapiro Ambulatory Care Center: Women's Health Group
Boston, Massachusetts, 02118
Gastroenterology Associates of Fairfield County
Bridgeport, Connecticut, 06606
Gastroenterology Associates
Bristol, Tennessee, 37620
Commonwealth Clinical Studies PLLC
Brockton, Massachusetts, 02302
NCH Medical Group
Buffalo Grove, Illinois, 60089
HealthCare Partners
Burbank, California, 91506
Carolina Digestive Health Associates
Charlotte, North Carolina, 28262
Charlottesville Medical Research
Charlottesville, Virginia, 22911
Gastroenterology Associates of Tidewater
Chesapeake, Virginia, 23320
Metropolitan Gastroenterology Group
Chevy Chase, Maryland, 20815
Jesse Brown VAMC
Chicago, Illinois, 60612
Union Health Services
Chicago, Illinois, 60612
Union Health Services
Chicago, Illinois, 60652
REMEK Research
Chino, California, 91710
Ohio GI & Liver Institute
Cincinnati, Ohio, 45014
Consultants for Clinical Research
Cincinnati, Ohio, 45219
Ohio GI & Liver Institute
Cincinnati, Ohio, 45219
Iowa Digestive Disease Center
Clive, Iowa, 50325
Banks Hepatology Institute P.C.
College Park, Maryland, 20740
Digestive Disease Associates
Columbia, Maryland, 21044
Howard County GIDC
Columbia, Maryland, 21044
Russell Schub
Columbia, Maryland, 21044
Columbia Medical Practice
Columbia, Maryland, 21045
Gasro Center of Maryland
Columbia, Maryland, 21045
Gastro Center of Maryland
Columbia, Maryland, 21045
Carolina Digestive Health Associates
Concord, North Carolina, 28025
Carolina Digestive Health Associates
Davidson, North Carolina, 28036
Southern California Oncology
Downey, California, 90241
Commonwealth Clinical Studies PLLC
East Bridgewater, Massachusetts, 02333
Marshfield Clinic-Eau Claire Center
Eau Claire, Wisconsin, 54701
AGA Clinical Research Associates, LLC
Egg Harbor, New Jersey, 08234
HealthCare Partners Medical Group
El Monte, California, 91733
Centennial Medical Group
Elkridge, Maryland, 21075
Gastroenterology Associates
Elkridge, Maryland, 21075
Regional Gastroenterology Associates of Lancaster
Ephrata, Pennsylvania, 17522
Gastroenterology Associates of Fairfield County
Fairfield, Connecticut, 06824
Cumberland Research Associates
Fayetteville, North Carolina, 28304
University of Wisconsin Milwaukee
Franklin, Wisconsin, 53132
Southern California Oncology
Fullerton, California, 92835
CBM Pathology
Gaithersburg, Maryland, 20879
Gastro One
Germantown, Tennessee, 38138
HealthCare Partners
Glendale, California, 91204
HealthCare Partners
Glendale, California, 91208
Valley Gastro Consultants
Glendora, California, 91741
Gastrointestinal Research Group
Great Neck, New York, 11023
Carolina Digestive Health Associates
Harrisburg, North Carolina, 28075
Main Line Gastroenterology
Havertown, Pennsylvania, 19083
VA Hospital
Hines, Illinois, 60141
Atlanta Gastroenterology Associates
Hiram, Georgia, 30141
Gastroenterology Associates, PA
Houston, Texas, 77034
Advanced Clinical Research of Houston
Houston, Texas, 77062
Houston Medical Research Associates
Houston, Texas, 77090
HealthCare Partners
Huntington Park, California, 90255
Roudebush VA Medical Center
Indianapolis, Indiana, 46202
Mayo Clinic Florida
Jacksonville, Florida, 32224
Digestive Health Specialists, PA
Kernersville, North Carolina, 27284
Gastroenterology Associates of Clinical Research
Kingsport, Tennessee, 37660
Regional Gastroenterology Associates of Lancaster
Lancaster, Pennsylvania, 17604
Maryland Digestive Disease Center
Laurel, Maryland, 20707
Advanced Research Institute
Logan, Utah, 84341
Health Care Partners Medical Group
Long Beach, California, 90806
Health Care Partners San Antonio
Long Beach, California, 90807
VA Hospital
Long Beach, California, 90822
Healthcare Partners Medical Group
Los Angeles, California, 90015
HealthCare Partners
Los Angeles, California, 90043
HealthCare Partners
Los Angeles, California, 90063
Blue Ridge Medical Research
Lynchburg, Virginia, 24502
Southern California Oncology
Lynwood, California, 90262
UW Health West Clinic
Madison, Wisconsin, 53717
University of Wisconsin Madison
Madison, Wisconsin, 53792
Main Line Gastroenterology
Malvern, Pennsylvania, 19355
Atlanta Gastroenterology Associates
Marietta, Georgia, 30060
Atlanta Gastroenterology Associates
Marietta, Georgia, 30067
Marshfield Clinic
Marshfield, Wisconsin, 54449
Main Line Gastroenterology
Media, Pennsylvania, 19063
Melbourne GI Center
Melbourne, Florida, 32901
MIMA Century Research Associates
Melbourne, Florida, 32901
MGAGI Diagnostic and Therapeutic Center
Metairie, Louisiana, 70006
New Orleans Research Institute
Metairie, Louisiana, 70006
Suncoast Research Group
Miami, Florida, 33135
GI Care Center
Miami, Florida, 33173
Gastro Health P.L.
Miami, Florida, 33176
University of Wisconsin Milwaukee
Milwaukee, Wisconsin, 53215
Marshfield Clinic-Minocqua Center
Minocqua, Wisconsin, 54548
Facey Medical Foundation
Mission Hills, California, 91345
Healthcare Partners- Mission Plaza
Mission Hills, California, 91345
Healthcare Partners-Mission Hills
Mission Hills, California, 91345
Delta Research Partners, LLC
Monroe, Louisiana, 71201
REMEK Research
Montclair, California, 91763
HealthCare Partners Medical Group
Montebello, California, 90640
Monterey Bay GI Consultants Medical Group & Research Institute
Monterey, California, 93940
Furtura Research
Monterey Park, California, 91754
Healthcare Partners Medical Group
Monterey Park, California, 91754
Coastal Carolina Research Center
Mt. Pleasant, South Carolina, 29464
Southwest Gastroenterology
New Lenox, Illinois, 60451
Faculty Practice Associates
New York, New York, 10029
GI Clinic
New York, New York, 10029
Internal Medicine Associates
New York, New York, 10029
Mount Sinai School of Medicine
New York, New York, 10029
Practice Associates
New York, New York, 10029
Digestive and Liver Disease Specialists
Norfolk, Virginia, 23502
Gastroenterology Associates of Tidewater
Norfolk, Virginia, 23505
Clinical Research Associates of Tidewater
Norfolk, Virginia, 23507
Union Health Services
Norridge, Illinois, 60706
Southwest Gastroenterology
Oak Lawn, Illinois, 60453
Advanced Research Institute
Ogden, Utah, 84405
Diverse Research Solutions
Oxnard, California, 93030
Desert Oasis Healthcare
Palm Springs, California, 92262
Desert Regional Medical Center
Palm Springs, California, 92262
Avicenna Clinical Research
Palos Heights, Illinois, 60463
HealthCare Partners
Pasadena, California, 91105
Gastroenterology Associates
Pasadena, Maryland, 21122
Main Line Gastroenterology
Perkasie, Pennsylvania, 18944
PGC Endoscopy Center Inc.
Philadelphia, Pennsylvania, 19111
REMEK Research
Pomona, California, 91767
Northwest Gastroenterology Clinic, LLC
Portland, Oregon, 97210
Wake Research Associates
Raleigh, North Carolina, 27612
Health Care Partners
Redondo Beach, California, 90277
Advanced Research Institute
Reno, Nevada, 89511
Mayo Clinic Rochester
Rochester, Minnesota, 55905
Rockford Gastroenterology Associates, LTD
Rockford, Illinois, 61107
Professional Quality Research, Inc.
Round Rock, Texas, 78681
Institute for Medical Research
Sacramento, California, 95816
Salt Lake Research, PLLC
Salt Lake City, Utah, 84107
Sharp-Rees-Stealy Medical Group
San Diego, California, 92101
Sharp-Rees-Stealy Medical Group
San Diego, California, 92123
Advanced Research Institute
Sandy City, Utah, 84094
Sansum Clinic
Santa Barbara, California, 93105
Sansum Clinic
Santa Barbara, California, 93110
Santa Monica Research Institute
Santa Monica, California, 90404
Mayo Clinic Scottsdale
Scottsdale, Arizona, 85259
Louisiana Research Center
Shreveport, Louisiana, 71103
Miami Research Associates
South Miami, Florida, 33143
Lakeview Medical Center
Suffolk, Virginia, 23434
Gastrointestinal Specialists
Taunton, Massachusetts, 02780
Health Care Partners Medical Group
Torrance, California, 90503
South Bay Gastroenterology Medical Group
Torrance, California, 90505
Center for Digestive Health
Troy, Michigan, 48098
Desert Sun Clinical Research, LLC
Tucson, Arizona, 85710
Tujunga Medical Group
Tujunga, California, 91042
Digestive Health Specialists of Tyler
Tyler, Texas, 75701
Healthcare Partners-Valencia
Valencia, California, 91355
Healthcare Partners- Van Nuys
Van Nuys, California, 91405
Gastroenterology Associates of Tidewater
Virginia Beach, Virginia, 23462
Metropolitan Gastroenterology Group, PC
Washington D.C., District of Columbia, 20006
Marshfield Clinic-Weston Center
Weston, Wisconsin, 54476
Hanover Medical Specialists
Wilmington, North Carolina, 28401
New Hanover Regional Medical Center
Wilmington, North Carolina, 28401
Wilmington Gastroenterology Associates
Wilmington, North Carolina, 28403
Digestive Health Specialists, PA
Winston-Salem, North Carolina, 27103
Atlanta Gastroenterology Associates
Woodstock, Georgia, 30188
Main Line Gastroenterology
Wynnewood, Pennsylvania, 19096
Southern California Oncology
Yorba Linda, California, 92886
Canada2 sites
University of Calgary
Calgary, Alberta, T2N 4Z6
Alberta Health Services
Calgary, Alberta, T2WIS7
About this study
Official title: Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer: DeeP-C Study
The primary objective is to determine the sensitivity and specificity of the Exact Colorectal Cancer (CRC) screening test for colorectal cancer, using colonoscopy as the reference method. Lesions will be confirmed as malignant by histopathologic examination.
The secondary objective is to compare the performance of the Exact CRC screening test to a commercially available FIT assay, both with respect to cancer and advanced adenoma. Lesions will be confirmed as malignant or precancerous by colonoscopy and histopathologic examination.
Read the detailed description
Patients who are at average risk of developing colorectal cancer who are eligible for colorectal cancer screening will be asked to collect a single stool sample for the Exact CRC screening test and for the commercially available FIT assay. Subjects will undergo colonoscopy within 90 days of enrollment. Representative histopathology slides from tissue biopsied or excised during colonoscopy and representative histopathology slides resulting from subsequent definitive surgery may be retrieved in order to be evaluated by central pathology to confirm diagnosis and staging.
- Keywords
- Cancer, Colorectal Cancer, Neoplasm, Colorectal Neoplasm, Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Neoplasms by Site, Neoplasms, Digestive System Diseases, Gastrointestinal Diseases, Colonic Diseases, Intestinal Diseases, Rectal Diseases
- Medical subject headings
- Colorectal Neoplasms, Digestive System Diseases, Colonic Diseases, Neoplasms, Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Neoplasms by Site
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Average risk patients | Subjects will be men and women, 50-84 years of age, inclusive, who are at average risk of developing colorectal cancer. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Sensitivity and Specificity of the Exact CRC Screening Test With Comparison to Colonoscopy, Both With Respect to Cancer.
An optical colonoscopic procedure is the reference method. Lesions will be confirmed as malignant by histopathologic examination. The DNA test includes quantitative molecular assays for KRAS mutations, aberrant NDRG4 and BMP3 methylation, and Beta-actin, plus a hemoglobin immunoassay. Results were generated with the use of a logistic-regression algorithm, with values of 183 or more considered to be positive. FIT values of more than 100 ng of hemoglobin per milliliter of buffer were considered to be positive. Tests were processed independently of colonoscopic findings. The test functions as a screening tool by generating a score, based on the detection of hemoglobin and multiple DNA methylation and mutational markers, together with an assessment of the total amount of human DNA in each sample. Sensitivity= 100*(multitarget DNA or FIT positive test/positive colonoscopy); Specificity= 100*(multitarget DNA or FIT negative test/negative colonoscopy).
Measured: 90 Days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Jul 2011 (estimated)
- Study startJun 2011
- Primary completionFeb 2013
- Study completionMay 2013
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Colorectal NeoplasmsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 12,776 participants (actual)
Sponsor and investigators
- Lead sponsor
- Exact Sciences Corporation
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Thomas Imperiale, MD, Principal investigator, Principal Study Investigator
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01397747
- Sponsor's protocol ID
- Exact Sciences 2011-01
- Acronym
- DeeP-C
- Status last verified
- Nov 2015
- First submitted
- 18 Jul 2011
- Last updated
- 3 Dec 2015
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Publications
Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP, Ahlquist DA, Berger BM. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014 Apr 3;370(14):1287-97. doi: 10.1056/NEJMoa1311194. Epub 2014 Mar 19.
PubMed 24645800Garg SK, Hintz CF, Kolarik HJ, Mau B, Hubers J, Arce V, Ebner DW, Gurudu SR, Bi Y, Greenwood J, Kisiel JB, Chaudhary R. Longitudinal Data From a Large, Multitarget Stool DNA Colorectal Cancer Screening Program. Am J Gastroenterol. 2026 Sep 3. doi: 10.14309/ajg.0000000000004196. Online ahead of print.
PubMed 42690929Imperiale TF, Gagrat ZD, Krockenberger M, Porter K, Ziegler E, Leduc CM, Matter MB, Olson MC, Limburg PJ. Algorithm Development and Early Performance Evaluation of a Next-Generation Multitarget Stool DNA Screening Test for Colorectal Cancer. Gastro Hep Adv. 2024 May 17;3(6):740-748. doi: 10.1016/j.gastha.2024.05.002. eCollection 2024.
PubMed 39280922Ebner DW, Rushlow D, Mou J, Porter K, Finney Rutten LJ, Limburg P, Sancar F, Imperiale TF. Stool-Based Colorectal Cancer Screening Test Performance Characteristics in Those With and Without Hemorrhoids. Mayo Clin Proc Innov Qual Outcomes. 2023 Jul 19;7(4):320-326. doi: 10.1016/j.mayocpiqo.2023.06.003. eCollection 2023 Aug.
PubMed 37502338
Study at a glance
From the registry record, last updated by the sponsor on 3 Dec 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer: DeeP-C Study
- ClinicalTrials.gov ID
- NCT01397747
- Acronym / sponsor ID
- DeeP-C / Exact Sciences 2011-01
- Keywords
- Cancer, Colorectal Cancer, Neoplasm, Colorectal Neoplasm, Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Neoplasms by Site
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 12,776 participants (actual)
- Lead sponsor
- Exact Sciences CorporationIndustry (pharma, biotech, devices)
- Study start
- Jun 2011
- Primary completion
- Feb 2013 (actual)
- Study completion
- May 2013 (actual)
- First posted
- 20 Jul 2011 (estimated)
- Results
- Posted 3 Dec 2015
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary objective is to determine the sensitivity and specificity of the Exact Colorectal Cancer (CRC) screening test for colorectal cancer, using colonoscopy as the reference method. Lesions will be confirmed as malignant by histopathologic examination.
The secondary objective is to compare the performance of the Exact CRC screening test to a commercially available FIT assay, both with respect to cancer and advanced adenoma. Lesions will be confirmed as malignant or precancerous by colonoscopy and histopathologic examination.
Detailed description
Patients who are at average risk of developing colorectal cancer who are eligible for colorectal cancer screening will be asked to collect a single stool sample for the Exact CRC screening test and for the commercially available FIT assay. Subjects will undergo colonoscopy within 90 days of enrollment. Representative histopathology slides from tissue biopsied or excised during colonoscopy and representative histopathology slides resulting from subsequent definitive surgery may be retrieved in order to be evaluated by central pathology to confirm diagnosis and staging.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Average risk patients | – | –Subjects will be men and women, 50-84 years of age, inclusive, who are at average risk of developing colorectal cancer. |
Who may qualify
- Ages
- 50 to 84 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Patients at average risk of developing colorectal cancer.
Key inclusion criteria (5 listed)
- Subject is average risk for development of colorectal cancer (as defined by the inclusion and exclusion criteria below).
- Subject is able and willing to undergo a screening colonoscopy within 90 days of enrollment.
- Subject is 50 to 84 years of age inclusive.
- Subject is able to comprehend, sign, and date the written informed consent document to participate in the study.
- Subject is able and willing to provide stool samples according to written instructions provided to them.
Key exclusion criteria (19 listed)
- Subject has any condition which, in the opinion of the investigator should preclude participation in the study.
- Subject has undergone colonoscopy within the previous nine (9) years.
- Subject has undergone any double-contrast barium enema, virtual (CT-based) colonoscopy, or flexible sigmoidoscopy within the previous five (5) years.
- Subject has a history of colorectal cancer or adenoma.
- Subject has a history of aerodigestive tract cancer.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Sensitivity and Specificity of the Exact CRC Screening Test With Comparison to Colonoscopy, Both With Respect to Cancer.
Time frame: 90 Days
An optical colonoscopic procedure is the reference method. Lesions will be confirmed as malignant by histopathologic examination. The DNA test includes quantitative molecular assays for KRAS mutations, aberrant NDRG4 and BMP3 methylation, and Beta-actin, plus a hemoglobin immunoassay. Results were generated with the use of a logistic-regression algorithm, with values of 183 or more considered to be positive. FIT values of more than 100 ng of hemoglobin per milliliter of buffer were considered to be positive. Tests were processed independently of colonoscopic findings. The test functions as a screening tool by generating a score, based on the detection of hemoglobin and multiple DNA methylation and mutational markers, together with an assessment of the total amount of human DNA in each sample. Sensitivity= 100*(multitarget DNA or FIT positive test/positive colonoscopy); Specificity= 100*(multitarget DNA or FIT negative test/negative colonoscopy).
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Dec 2015.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Results publication: PubMed 24645800Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP, Ahlquist DA, Berger BM. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014 Apr 3;370(14):1287-97. doi: 10.1056/NEJMoa1311194. Epub 2014 Mar 19.
- Derived from this study: PubMed 42690929Garg SK, Hintz CF, Kolarik HJ, Mau B, Hubers J, Arce V, Ebner DW, Gurudu SR, Bi Y, Greenwood J, Kisiel JB, Chaudhary R. Longitudinal Data From a Large, Multitarget Stool DNA Colorectal Cancer Screening Program. Am J Gastroenterol. 2026 Sep 3. doi: 10.14309/ajg.0000000000004196. Online ahead of print.
- Derived from this study: PubMed 39280922Imperiale TF, Gagrat ZD, Krockenberger M, Porter K, Ziegler E, Leduc CM, Matter MB, Olson MC, Limburg PJ. Algorithm Development and Early Performance Evaluation of a Next-Generation Multitarget Stool DNA Screening Test for Colorectal Cancer. Gastro Hep Adv. 2024 May 17;3(6):740-748. doi: 10.1016/j.gastha.2024.05.002. eCollection 2024.
- Derived from this study: PubMed 37502338Ebner DW, Rushlow D, Mou J, Porter K, Finney Rutten LJ, Limburg P, Sancar F, Imperiale TF. Stool-Based Colorectal Cancer Screening Test Performance Characteristics in Those With and Without Hemorrhoids. Mayo Clin Proc Innov Qual Outcomes. 2023 Jul 19;7(4):320-326. doi: 10.1016/j.mayocpiqo.2023.06.003. eCollection 2023 Aug.
Related trials for Colorectal Neoplasms
RecruitingPhase 1
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-)
RecruitingObservational study
Evaluation for NCI Surgery Branch Clinical Research Protocols
Synovial Cell Cancer, Melanoma
RecruitingObservational study
Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer
Colorectal Cancer, Sarcopenia
Not yet recruiting
Mind-Body Interventions for the Improvement of Quality of Life, Stress, and Sleep Quality Among Survivors of Breast, Prostate, Endometrial, or Colorectal Cancer
Breast Cancer Stage I, Colorectal Cancer
RecruitingPhase 2
FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer
Ras-mutated Metastatic Colorectal Cancer, mCRC
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Thomas Imperiale, MD principal investigator
Principal Study Investigator
184 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Colorectal Neoplasms and Digestive System Diseases, run by Exact Sciences Corporation at 184 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Dec 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 184 sites in United States, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 3 Dec 2015). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Sensitivity and Specificity of the Exact CRC Screening Test With Comparison to Colonoscopy, Both With Respect to Cancer. (time frame: 90 Days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01397747, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Dec 2015.